Arrowhead Pharmaceuticals (ARWR) Income from Continuing Operations (2010 - 2026)
Arrowhead Pharmaceuticals (ARWR) posted Income from Continuing Operations of 137572000.0 for Q1 2026, down 587.12% on a QoQ basis from 28242000.0 in Q4 2025, and down 137.4% year-over-year from 367863000.0 in Q1 2025.
Arrowhead Pharmaceuticals (ARWR) Income from Continuing Operations (2010 - 2026) Analysis & Trends
Arrowhead Pharmaceuticals' Income from Continuing Operations history runs 17 years deep, the most recent figure standing at 137572000.0 for Q1 2026.
- Quarterly Income from Continuing Operations fell 137.4% year-over-year to 137572000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 271898000.0 (down 75.8% YoY) and the FY2025 annual result came in at 30114000.0, up 104.94% from the prior year.
- Income from Continuing Operations was 137572000.0 for Q1 2026 at Arrowhead Pharmaceuticals, down from 28242000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 367863000.0 in Q1 2025 and bottomed at 178689000.0 in Q2 2025.
- A 5-year average of 59518411.76 and a median of 104125000.0 in 2023 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2024 — Income from Continuing Operations tumbled 366.37% — and 2025, when it jumped 389.67%.
- Arrowhead Pharmaceuticals' Income from Continuing Operations stood at 41794000.0 in 2022, then slumped by 223.91% to 135376000.0 in 2023, then dropped by 29.43% to 175218000.0 in 2024, then soared by 116.12% to 28242000.0 in 2025, then plunged by 587.12% to 137572000.0 in 2026.
- Business Quant data shows ARWR's Income from Continuing Operations at 137572000.0 in Q1 2026, 28242000.0 in Q4 2025, and 16121000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 498.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -453.82 Mn |
| 10 | Arrowhead Pharmaceuticals | 12.14 Bn | 10.36 Bn | - | -137.57 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -137.57 Mn |
| Dec 31, 2025 | 28.24 Mn |
| Sep 30, 2025 | 16.12 Mn |
| Jun 30, 2025 | -178.69 Mn |
| Mar 31, 2025 | 367.86 Mn |
| Dec 31, 2024 | -175.22 Mn |
| Sep 30, 2024 | -173.33 Mn |
| Jun 30, 2024 | -173.98 Mn |
| Mar 31, 2024 | -127.00 Mn |
| Dec 31, 2023 | -135.38 Mn |
| Sep 30, 2023 | -111.02 Mn |
| Jun 30, 2023 | -104.13 Mn |
| Mar 31, 2023 | 47.68 Mn |
| Dec 31, 2022 | -41.79 Mn |
| Sep 30, 2022 | -85.94 Mn |
| Jun 30, 2022 | -72.05 Mn |
| Mar 31, 2022 | 44.37 Mn |
| Dec 31, 2021 | -62.87 Mn |
| Sep 30, 2021 | -63.37 Mn |
| Jun 30, 2021 | -29.92 Mn |